Poolbeg Pharma (LON:POLB) Stock Price Up 9.8% – Should You Buy?

Poolbeg Pharma PLC (LON:POLB)’s share price rose 9.8% on Wednesday . The company traded as high as GBX 4.70 and last traded at GBX 4.70. Approximately 983,829 shares were traded during trading, a decline of 24% from the average daily volume of 1,287,200 shares. The stock had previously closed at GBX 4.28.

Wall Street Analyst Weigh In

Separately, Shore Capital Group reissued a “house stock” rating on shares of Poolbeg Pharma in a report on Wednesday, January 28th.

Poolbeg Pharma Stock Performance

The stock has a market cap of £33.84 million, a price-to-earnings ratio of -4.21 and a beta of 1.82. The company’s 50 day simple moving average is GBX 4.37 and its 200 day simple moving average is GBX 4.12.

About Poolbeg Pharma

Poolbeg Pharma plc (AIM: POLB) is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company’s lead asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). As such, POLB 001 could increase the number of patients that can receive these life-saving treatments, thereby increasing the market opportunity.